Document Detail


Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans.
MedLine Citation:
PMID:  9890409     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Amrinone-a phosphodiesterase III inhibitor-is used in the treatment of acute heart failure. In addition to its hemodynamic effects, amrinone has been shown to inhibit thromboxane synthesis in vitro. We investigated the effects of amrinone on thromboxane, prostaglandin, and leukotriene synthesis in humans. Eight healthy male volunteers took part in this single-blind study in which either amrinone (a 1.5-mg/kg bolus in 30 min and after that 10 microg/kg/min for 1 h 30 min) or placebo (0.9% NaCl) were infused. Amrinone infusion increased systolic blood pressure but had no significant effect on diastolic blood pressure or heart rate. Amrinone did not modulate thromboxane B2 synthesis stimulated by either spontaneous clotting or calcium-ionophore A23187 in whole blood. Amrinone had no effects on prostaglandin E2 or leukotriene E4 production in A23187-stimulated whole blood, nor did it affect urinary excretion of 11-dehydrothromboxane B2 or 2,3-dinor-6-keto-prostaglandin F1alpha, the index metabolites of thromboxane A2 and prostacyclin productions, respectively. We conclude that amrinone has no effects on eicosanoid production in humans at the dose level used in this study, and that the hemodynamic effects noticed are not mediated via cyclooxygenase or lipoxygenase products of arachidonic acid metabolism.
Authors:
T Kerttula; J Alanko; E Seppälä; A Riutta; I Mucha; E Sievi; S Kaukinen
Related Documents :
8569549 - Hypothesis on cellular atp depletion and adenosine release as causes of heart failure a...
1464829 - Effects of aortic pressure and vasoactive agents on the vascular resistance of the vasa...
9045879 - Role of mgadp in the development of diastolic dysfunction in the intact beating rat heart.
6510459 - Cardiovascular effects of two different xanthines in healthy subjects. studies at rest,...
3959089 - Relation between the phosphocreatine to atp ratio determined by 31p nuclear magnetic re...
861719 - Effect of insulin hypoglycemia upon cerebral energy metabolism and eeg activity in the ...
19138169 - Central blood pressure and hypertension: role in cardiovascular risk assessment.
2258789 - Pseudohypertension in hypertensive patients on multiple drug therapy.
791329 - Double-blind trial of labetalol.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  33     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1999 Jan 
Date Detail:
Created Date:  1999-03-11     Completed Date:  1999-03-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  140-3     Citation Subset:  IM    
Affiliation:
Department of Clinical Chemistry, Tampere University Hospital, University of Tampere, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Amrinone / pharmacology*
Arachidonic Acids / metabolism*
Humans
Leukotrienes / metabolism
Male
Phosphodiesterase Inhibitors / pharmacology*
Prostaglandins / metabolism,  urine
Thromboxanes / metabolism,  urine
Chemical
Reg. No./Substance:
0/Arachidonic Acids; 0/Leukotrienes; 0/Phosphodiesterase Inhibitors; 0/Prostaglandins; 0/Thromboxanes; 60719-84-8/Amrinone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of arrhythmias in the Circadian Antiischemia Program in Europe (CAPE) study.
Next Document:  Hemodynamic response to oxygen administration in chronic heart failure: role of chemoreflexes.